Skip to main content

Main navigation

  • About
    • Members
    • Our Team
    • Annual Report
    • Rutgers-NPC Health Policy & Communications Fellowship
    • NPC Summer Scholars
    • Contact Us
  • Topics
    • Health Spending
      • IRA & Medicare Drug Price Negotiation
      • 340B Drug Pricing Program
      • Understanding Health Spending
      • Low-Value Care
      • Health Spend Management
    • Value Assessment
      • Value Assessment Frameworks
      • Value Assessment Methods
      • Elements of Value
    • Alternative Payment Models
      • Value-Based Contracts
      • Regulatory Barriers & Challenges
      • Paying for Cures
      • Accountable Care Organizations
      • Bundled Payments
      • Health Care Quality Measures
      • Clinical Pathways
    • Patient-Centered Formulary & Benefit Design
      • High-Deductible Health Plans
      • Value-Based Insurance Design
      • Utilization Management & Step Therapy
      • Formulary Development
      • Patient Cost Sharing
      • Individual Treatment Effects & Personalized Access
    • Evidence for Decision Making
      • Real-World Data
      • Real-World Evidence
      • Good Practices for Evidence
    • Biopharma Innovation
      • Impact on Outcomes & Spending
  • Resources
    • Research
    • Fact Sheets
    • Policy & Evidence Briefs
    • Letters & Comments
    • E.V.I.dently Today Blog
    • Newsletters
    • Events
    • CER Daily Newsfeed®
    • Press Room
      • NPC in the News
      • NPC Press Releases
    • Videos and Graphics
    • Stakeholder Resources
      • For Employers
      • For Patient Organizations
      • Going Below The Surface
  • Get Involved
    • Become a Member
    • Submit a Research Proposal
    • Start a Career
National Pharmaceutical Council

Offscreen menu

User account menu

  • Member Resources

The IRA and Orphan Drugs: A Patient-Focused Look at Orphan Drug Designations Following Expansion of the Orphan Drug Exclusion

  • Read more about The IRA and Orphan Drugs: A Patient-Focused Look at Orphan Drug Designations Following Expansion of the Orphan Drug Exclusion

U.S. Biopharmaceutical Leadership Amidst Changing Price Regulation

  • Read more about U.S. Biopharmaceutical Leadership Amidst Changing Price Regulation

Therapeutic Characteristics of the Proposed Mandatory International Reference Pricing Models

  • Read more about Therapeutic Characteristics of the Proposed Mandatory International Reference Pricing Models

How Mandatory International Reference Pricing Uses Prices From Countries That Don't Meet Stated Criteria

  • Read more about How Mandatory International Reference Pricing Uses Prices From Countries That Don't Meet Stated Criteria

NPC Submits Comments to CMS on Proposed Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program

  • Read more about NPC Submits Comments to CMS on Proposed Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program

Assessing Commercial Health Plan Responsiveness to FDA Label Changes

  • Read more about Assessing Commercial Health Plan Responsiveness to FDA Label Changes

Innovative Contracting for Gene Therapies: Current Landscape and Perspectives on the Future of Gene Therapy Financing in the USA

  • Read more about Innovative Contracting for Gene Therapies: Current Landscape and Perspectives on the Future of Gene Therapy Financing in the USA

New Research Explores Future of Gene Therapy Financing in the U.S.

  • Read more about New Research Explores Future of Gene Therapy Financing in the U.S.

Does Delaying Coverage for Accelerated Approval Treatments Disproportionately Impact Patients With High Unmet Needs?

  • Read more about Does Delaying Coverage for Accelerated Approval Treatments Disproportionately Impact Patients With High Unmet Needs?

NPC Submits Comments to CMS Regarding the Hospital Outpatient Prospective Payment System (OPPS) Proposed Rule for CY 2026

  • Read more about NPC Submits Comments to CMS Regarding the Hospital Outpatient Prospective Payment System (OPPS) Proposed Rule for CY 2026

Pagination

  • Next page
  • Page 2
  • Next page
Subscribe to Policy & Regulatory Barriers

Let's stay in touch.

Subscribe to our newsletter.
© 2026 NPC. All rights reserved.

Footer Menu

  • Accessibility
  • Privacy Policy
  • Terms of Use
  • Contact Us

Footer Social Links Menu

  • Twitter image/svg+xml
  • Linkedin
  • Youtube